Plain-English translation of NCT07811726 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing NT-101, a new eye drop treatment designed to help people with wet age-related macular degeneration (a condition where abnormal blood vessels grow under the macula, the part of the eye responsible for sharp central vision). You would receive either the medication or a placebo (inactive drops) and use them twice daily for 12 weeks while researchers track how well the treatment works and whether it is safe.
Wet age-related macular degeneration can cause significant vision loss and currently requires frequent injections into the eye. This trial is exploring whether this new medication in eye drop form could offer a less invasive treatment option for patients with this condition.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic for screening appointments over 4 weeks, then begin a 12-week treatment period where you instill two drops of the medication (or placebo) into your eye twice daily. During treatment, you would return to the clinic at weeks 4, 8, and 12 for eye exams that include vision testing, imaging scans (OCT and photographs), and checks for side effects. After your last dose, you would have one follow-up visit 4 weeks later to ensure everything is safe.
AI-generated summary from trial data · Oct 6, 2026 · Not medical advice
United States